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Circumscribed Juvenile Pityriasis Rubra Pilaris  
(Type 4) Koebnerising after a Hot Water Burn:  
Mild Disease with Maximum Koebner Response
Dear Editor,
Pityriasis rubra pilaris (PRP) is a chronic, inflamma-
tory, papulosquamous skin disorder that is character-
ized by follicular hyperkeratosis and reddish-orange, 
scaling dermatitis with islands of normal skin (1,2). 
PRP is classified into 5 groups based on clinical fea-
tures. Type 4 PRP is characterized by well-demarcat-
ed, hyperkeratotic erythematous plaques localized 
on the elbows and knees with palmoplantar kerato-
derma (1,2).
An 8-year-old girl presented to our clinic with ery-
thematous plaques on both elbows, the legs, and the 
knees. Plantar keratoderma was noticed on clinical 
examination. The lesions had started on the elbows 
and knees about a year ago. The lesions on the leg 
were surrounded by an irregular, hyperpigmented 
border. On close inspection, the plaques were formed 
by follicular papules and mild desquamation was no-
ticed. Upon questioning, it was learned that the le-
sions on the leg with hyperpigmented borders had 
emerged after a hot water burn three months ago 
and that they were localized exactly on the burned 
areas of the skin (Figure 1).
A biopsy was performed on the new lesions, and 
histopathological evaluation revealed parakeratosis 
with alternating orthokeratosis, irregular hyperkera-
tosis, keratotic plugs, and a mild perivascular lympho-
cytic infiltration around the blood vessels (Figure 2). A 
diagnosis of PRP was established. 
The Koebner phenomenon (KP) is described as 
the development of lesions in previously normal skin 
after exposure to internal or external trauma such as 
surgical incisions, burns, friction, insect bites, and al-
lergic and irritant reactions (3). The pathogenesis of KP 
is not fully understood, but epidermal cell injury and 
dermal inflammation have been proposed as having a 
role in the pathophysiology (4). Experimental studies 
on the mechanism of KP have been performed most-
ly on patients with psoriasis (3). Disease severity, early 
age of disease onset, and multiple previous therapies 
have been found to be associated with KP (5,6). KP has 
previously been reported after injury with the sharp 
end of a stick in type 3 PRP, a generalized PRP form 
(7). However, our patient was diagnosed with type 4 
PRP, which is a localized form of the disorder. Griffiths 
reported type 4 PRP does not evolve to generalized 
forms (8). In this respect, our case was interesting as 
maximum Koebner response was observed despite 
the mild PRP. We therefore believe that disease se-
verity is not a determining factor in KP and that the 
severity of skin damage plays a crucial role. We also 
think that changes in the cytokine milieu in the burn 
area may be responsible for KP, as levels of IL-17 and 
IL-22, which have been shown to be upregulated in 
burns, also play a role in PRP pathogenesis (9,10). The 
disease onset at an early age might have also had a 
contributing role in the Koebner response in this pa-
tient. The hyperpigmented borders of the Koebner-
ized plaques were also notable as they were spared 
from KP. Some spared areas were also seen within the 
Koebnerized plaques themselves. A threshold level of 
trauma is thought to be necessary for inducing KP (3). 
Figure 1. (A) Erythematous plaques formed by follicular 
papules and mild desquamation on both elbows, the knees, 
and legs. Koebnerized plaques surrounded by hyperpig-
mented borders. (B) Image of the lesions on the leg from 
the lateral aspect. The irregular shape of hyperpigmented 
borders due to a splash of water.
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The clinical picture of our patient may indicate that 
the skin damage was much less severe in some areas 
of the burn, especially in the periphery, and that KP 
was therefore not observed in these areas. 
Our case clearly demonstrates that the Koebner 
response is not related to disease severity. We be-
lieve that the type of trauma is an important factor 
in determining the severity of skin damage and the 
changes in the cytokine milieu in the involved skin. 
Early disease onset also seems to contribute to the 
development of KP. Further studies investigating the 
mechanism of KP in various skin disorders are neces-
sary. As far as we are aware, this is the first case re-
porting Koebnerization in the circumscribed juvenile 
form of PRP.
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Figure 2. (A) Keratotic plugs, irregular hyperkeratosis, alter-
nating orthokeratosis and parakeratosis (hematoxylin and 
eosin, ×50); (B) perivascular lymphocytic infiltration around 
the blood vessels on histopathological examination (hema-
toxylin and eosin, ×100).
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Successful Treatment with Fusidic Acid in a Patient 
with Folliculitis Decalvans
Dear Editor,
Folliculitis decalvans (FD) is a rare form of prima-
ry neutrophilic cicatricial alopecia. It is a highly dis-
tressing disease that affects young and middle-aged 
adults, with a slight male predominance (1).
The most frequent clinical manifestations are folli-
cular pustules and diffuse and perifollicular erythema 
that heal with centrifugal scarring. Follicular tufting, 
erosions, and hemorrhagic crusts can also be present, 
and this alopecia is most often located at the ver-
tex and occipital area. Patients frequently complain 
about pain, itching, or burning sensations, and the 
involvement of other body areas is rare (2).
The pathogenesis of this disease remains unclear. 
Staphylococcus aureus and other hair follicle bacteria 
can often be isolated from the pustules, suggesting 
the role of a bacterial infection in its etiology. A defect 
in the host’s immune response can also be postula-
ted by reports of familial cases and the appearance 
of FD in patients with immunity dysfunctions. Other 
mechanical factors have been suggested, such as 
structural abnormalities of the follicle or local inflam-
mation (2).
Management of this alopecia is difficult and its 
course is typically chronic and relapsing. The treat-
ment aim is to stop inflammation and further irrever-
sible destruction of hair follicles. Antibiotics remain 
the first-line therapy, due both to their anti-inflamma-
tory and antimicrobial properties (1). Although topi-
cal fusidic acid is widely used as adjuvant treatment, 
there are few data regarding its oral use. 
We report a case of folliculitis decalvans success-
fully treated with oral fusidic acid. Our patient was a 
41-year old Cape Verdean woman with a two month 
history of alopecia with painful, purulent discharge 
at the vertex of the scalp. The patient was diagnosed 
with human immunodeficiency virus type 1 (HIV-1) 
infection 5 years prior and was stable on her regimen 
of efavirenz, tenofovir, and emtricitabine, with unde-
tectable viral load. She denied application of topical 
or capillary products. Dermatological examination re-
vealed a patch of cicatricial alopecia with crusts and 
follicular pustules (Figure 1). Direct microscopic exa-
mination and mycological culture showed no fungal 
element. A diagnosis of folliculitis decalvans was es-
tablished and the patient was started on oral fusidic 
acid at a dose of 500 mg three times a day. Betame-
thasone dipropionate 0.05% and salicylic acid 3% lo-
tion as well as azelaic acid 5% lotion were also applied 
to the affected area once daily. After two months of 
treatment, the patient showed clinical improvement, 
with less erythema and suppuration of the affected 
scalp. A partial hair regrowth was noted, mainly at the 
periphery. Subsequently the patient maintained only 
topical therapy, and no recurrences were observed 
after 6-months of follow-up. 
Fusidic acid is useful in the treatment of skin and 
soft tissue infections, particularly those due to S. au-
reus, as shown by randomized controlled studies (3). 
The clinical efficacy of fusidic acid in the treatment of 
folliculitis decalvans has been reported previously. 
Bogg was the first to describe this useful effect (4). 
Sutter also reported good results with fusidic acid 
used both topically and orally (500 mg three times a 
day) (5). However, both failed to report the treatment 
duration or the outcome on discontinuation. Abeck 
described three patients that responded to a three 
Figure 1. Large atrophic alopecic patch at the occipital re-
gion with areas of follicular tufting and peripheral crusts.
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